Phenotypic resistance in mycobacteria: Is it because I am old or fat that I resist you?

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 10, 2015, Pages 2823-2827

  Hammond, Robert J H ^a   Baron, Vincent O ^a   Oravcova, Katarina ^a   Lipworth, Sam ^a   Gillespie, Stephen H ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; LIPID; RIFAMPICIN; ANTIINFECTIVE AGENT; FAT DROPLET;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CELL AGING; FLOW CYTOMETRY; LIPID STORAGE; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM MARINUM; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PHENOTYPE; SEPARATION TECHNIQUE; STAINING; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOBACTERIOSIS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; LIPID DROPLETS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; PHENOTYPE;

EID: 84943747320     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv178     Document Type: Article

References (22)

1. Russell S. The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. Am J Trop Med Hyg 2004; 71: 147-55.
2. Rajeswari R, Balasubramanian R, Muniyandi M et al. Socio-economic impact of tuberculosis on patients and family in India. Int J Tuberc Lung Dis 1999; 3: 869-77.
3. Fox W. Whither short-course chemotherapy? Br J Dis Chest 1981; 75: 331-57.
4. Fox W. General considerations in intermittent drug therapy of pulmonary tuberculosis. Postgrad Med J 1971; 47: 729-36.
5. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-54.
6. Teixeira EG, Menzies D, Comstock GW et al. Latent tuberculosis infection among undergraduate medical students in Rio de Janeiro State, Brazil. Int J Tuberc Lung Dis 2005; 9: 841-7.
7. Daniel J, Maamar H, Deb C et al. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancylike phenotype in lipid-loaded macrophages. PLoS Pathog 2011; 7: e1002093.
8. Rodríguez JC, Ruiz M, López M et al. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002; 20: 464-7.
9. Gomez JE, McKinney JD M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004; 84: 29-44.
10. D'Avila H, Melo RC, Parreira GG et al. Mycobacterium bovis bacillus Calmette-Gué rin induces TLR2-mediated formation of lipid bodies: intracellular domains for eicosanoid synthesis in vivo. J Immunol 2006; 176: 3087-97.
11. Garton NJ, Christensen H, Minnikin DE et al. Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum. Microbiology 2002; 148: 2951-8.
12. Barer MR, Garton NJ. Mycobacterial lipid bodies and the chemosensitivity and transmission of tuberculosis. In: Handbook of Hydrocarbon and Lipid Biology. Springer, 2010; 3185-93.
13. Garton NJ, Waddell SJ, Sherratt AL et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 2008; 5: e75.
14. Billington OJ, McHugh TD, Gillespie SH. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999; 43: 1866-9.
15. Zumla AI, Gillespie SH, Hoelscher M et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 2014; 14: 327-40.
16. TatoM, de la Pedrosa EG, CantónRet al. In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates. Int J Antimicrob Agents 2006; 28: 75-8.
17. Vandal OH, Nathan CF, Ehrt S. Acid resistance in Mycobacterium tuberculosis. J Bacteriol 2009; 191: 4714-21.
18. Filippini P, Iona E, Piccaro G et al. Activity of drug combinations against dormant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010; 54: 2712-5.
19. Hampshire T, Soneji S, Bacon J et al. Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: a model for persistent organisms? Tuberculosis (Edinb) 2004; 84: 228-38.
20. Deb C, Lee CM, Dubey VS et al. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drugtolerant, dormant pathogen. PLoS One 2009; 4: e6077.
21. Piccaro G, Giannoni F, Filippini P et al. Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions. Antimicrob Agents Chemother 2013; 57: 1428-33.
22. Mukamolova GV, Turapov O, Malkin J et al. Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am J Respir Crit Care Med 2010; 181: 174-80.